Implications of corticotropin releasing factor in targeted anticancer therapy

Byung Jin Kim, Harlan P. Jones

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


There is a need to develop novel anticancer therapies that eliminate adverse side effects produced by current treatments. Corticotropin releasing factor (CRF), an endogenous neuroedocrine factor, which typically regulates biological and psychological indicators of stress, has recently been found to be expressed by tumor malignancies. Here, we discuss the implications of CRF as a target for antitumor therapy through regulation of tumor immune escape mechanisms.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalJournal of Pharmacy Practice
Issue number2
StatePublished - Apr 2010


  • Cancer
  • Chemokine
  • Corticotropin releasing factor
  • Cytokine
  • Drug therapy
  • Immune


Dive into the research topics of 'Implications of corticotropin releasing factor in targeted anticancer therapy'. Together they form a unique fingerprint.

Cite this